SAWAI GROUP HOLDINGS Co., Ltd. (JP:4887)
:4887
Want to see JP:4887 full AI Analyst Report?
Top Page
SAWAI GROUP HOLDINGS Co., Ltd.
(4887)
Select Model
Select Model
Rating:55Neutral
Price Target:
¥1,784.00
▼(-24.37% Downside)
Action:Reiterated
Date:05/19/26
The score is mainly constrained by weaker financial quality signals—especially the sharp 2026 cash flow deterioration and margin compression—despite strong revenue growth and a generally sound balance sheet. Technicals add further pressure with a clear downtrend versus moving averages and bearish momentum, while valuation is mixed: a solid dividend yield offsets a relatively higher P/E.
Positive Factors
Strong recent revenue acceleration
Nearly 50% reported revenue growth in 2026 demonstrates the company's ability to scale sales rapidly, likely from successful generic launches or market share gains. Durable top-line expansion improves fixed-cost absorption and supports longer-term operating leverage, funding capacity and strategic reinvestment.
Negative Factors
Sustained margin compression
Material erosion in gross and net margins over several years indicates persistent pricing pressure, higher input costs or product-mix shifts in the generics franchise. Lower margin structure reduces incremental cash generation, constrains reinvestment, and makes returns more sensitive to cost volatility and competition.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong recent revenue acceleration
Nearly 50% reported revenue growth in 2026 demonstrates the company's ability to scale sales rapidly, likely from successful generic launches or market share gains. Durable top-line expansion improves fixed-cost absorption and supports longer-term operating leverage, funding capacity and strategic reinvestment.
Read all positive factors
SAWAI GROUP HOLDINGS Co., Ltd. (4887) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥175.86B
Dividend Yield2.28%
Average Volume (3M)299.27K
Price to Earnings (P/E)24.4
Beta (1Y)0.41
Revenue Growth6.69%
EPS Growth6.72%
CountryJP
Employees3,482
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)91.56
Shares Outstanding115,487,140
10 Day Avg. Volume288,420
30 Day Avg. Volume299,266
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.43
Price to Sales (P/S)1.27
P/FCF Ratio-42.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥2,533.33Price Target Upside7.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)167.57
Revenue Forecast (FY)¥216.18B
SAWAI GROUP HOLDINGS Co., Ltd. Business Overview & Revenue Model
Company Description
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage f...
How the Company Makes Money
SAWAI GROUP HOLDINGS makes money primarily through the sale of pharmaceutical products produced and marketed by its operating subsidiaries, with generics as the core revenue driver. Revenue is generated when the group sells finished-dose medicines...
SAWAI GROUP HOLDINGS Co., Ltd. Financial Statement Overview
Summary
Income Statement
68
Positive
Balance Sheet
72
Positive
Cash Flow
38
Negative
| Breakdown | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 201.68B | 189.02B | 176.86B | 200.34B | 193.82B |
| Gross Profit | 58.79B | 56.35B | 54.32B | 62.63B | 68.95B |
| EBITDA | 36.35B | 19.44B | 36.88B | 34.87B | -20.18B |
| Net Income | 10.44B | 11.97B | 13.70B | 12.67B | -28.27B |
Balance Sheet | |||||
| Total Assets | 359.92B | 354.62B | 382.02B | 364.17B | 349.50B |
| Cash, Cash Equivalents and Short-Term Investments | 28.99B | 38.78B | 26.37B | 33.08B | 47.72B |
| Total Debt | 105.02B | 95.11B | 87.13B | 77.07B | 70.80B |
| Total Liabilities | 181.36B | 180.77B | 163.99B | 151.43B | 149.42B |
| Stockholders Equity | 178.56B | 173.85B | 212.66B | 201.64B | 190.07B |
Cash Flow | |||||
| Free Cash Flow | -5.98B | 7.28B | 5.23B | -7.70B | 19.80B |
| Operating Cash Flow | 7.43B | 27.85B | 23.15B | 13.03B | 34.31B |
| Investing Cash Flow | -22.90B | 6.48B | -23.11B | -27.13B | -30.39B |
| Financing Cash Flow | 5.59B | -32.70B | 2.36B | -1.27B | -11.26B |
SAWAI GROUP HOLDINGS Co., Ltd. Technical Analysis
Negative
2359.00
Price Trends
2121.69
Negative
2224.16
Negative
2084.04
Negative
Market Momentum
-108.35
Positive
29.19
Positive
10.28
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4887, the sentiment is Negative. The current price of 2359 is above the 20-day moving average (MA) of 1996.95, above the 50-day MA of 2121.69, and above the 200-day MA of 2084.04, indicating a bearish trend. The MACD of -108.35 indicates Positive momentum. The RSI at 29.19 is Positive, neither overbought nor oversold. The STOCH value of 10.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4887.
SAWAI GROUP HOLDINGS Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | ¥76.70B | 11.02 | ― | 2.52% | 10.90% | 6.20% | |
68 Neutral | ¥54.39B | 38.20 | 5.01% | 2.39% | 17.31% | -24.31% | |
67 Neutral | ¥283.49B | 22.21 | ― | 2.12% | 6.58% | -8.74% | |
58 Neutral | ¥169.72B | 14.03 | 6.70% | 2.48% | 10.28% | 20.78% | |
55 Neutral | ¥175.86B | 24.45 | ― | 2.28% | 6.69% | 6.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | ¥191.44B | 37.55 | 12.02% | 2.14% | 5.44% | -72.35% |
* Healthcare Sector Average
JP:4887
SAWAI GROUP HOLDINGS Co., Ltd.
1,772.50
-32.71
-1.81%
JP:4547
Kissei Pharmaceutical Co
4,015.00
258.04
6.87%
JP:4553
Towa Pharmaceutical Co
3,890.00
879.94
29.23%
JP:4554
Fuji Pharma Co., Ltd.
2,193.00
928.62
73.44%
JP:4516
Nippon Shinyaku Co., Ltd.
4,119.00
784.26
23.52%
JP:4886
ASKA Pharmaceutical Holdings Co., Ltd.
2,830.00
572.34
25.35%
SAWAI GROUP HOLDINGS Co., Ltd. Corporate Events
Sawai Group Lifts Profitability and Dividends as It Refocuses on Domestic Generics
May 15, 2026
Sawai Group Holdings reported a 6.7% rise in revenue to ¥201.7 billion for the year ended March 31, 2026, with operating profit surging more than threefold as its core domestic pharmaceuticals business improved after exiting its U.S. operatio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.